ARCHIVES

Health Reform Bill Contains Unpleasant Surprises For Drug Manufacturers

This article is from The Cancer Letter archive.

Vol. 19 No. 43 | November 5, 1993

Download PDF Visit The Full Archive

Related Articles

Lymphoblastoid If Test Shows Toxicity Not From Impurity, Investigator Says

August 8, 1980

Challoner: We Recommended FDA Replace 510(k) Clearance

July 4, 2014

Nexavar Improves PFS In Phase III Trial

January 25, 2013

ACS Offers New Grants to Physicians

September 7, 1984

DCT Advisers Ok Expansion of Phase 1, Phase 2 Testing

July 10, 1992

NCI Biostatistician Calls For Reanalysis Of Canadian Breast Screening Study

February 10, 1995